A dog named Rosie's cancer treatment, aided by AI, has demonstrated the potential of personalized medicine. However, outdated regulations in Australia are hindering the adoption of such advanced AI-driven therapies for both humans and animals.
An Australian dog named Rosie received an AI-assisted mRNA vaccine that significantly shrunk her tumors, extending her life. Scientists at UNSW used AI to process genetic data, fast-tracking treatment design from years to months. However, outdated regulatory frameworks in Australia are seen as a major obstacle to adopting such AI-driven precision medicine for humans.
An Australian dog named Rosie received a life-extending cancer treatment developed with AI, but scientists warn outdated regulations are hindering Australia's potential to lead in AI-driven precision medicine.
Cross-border biotech deals between China and the US are facing increased complexity and potential slowdown due to US restrictions on investment and technology transfers, according to analysts. Despite challenges, innovation from China is expected to drive continued partnerships, with out-licensing agreements projected to reach $240 billion.
China held a forum in Berlin to promote imports from the EU, aiming to ease trade tensions and address its growing trade surplus. The event, attended by officials and executives, sought to showcase China's market potential amid rising regulatory hurdles and geopolitical shifts in Europe.
Chinese manufacturers exporting to the EU face new regulatory hurdles due to the Carbon Border Adjustment Mechanism (CBAM). The system requires detailed carbon intensity data, causing significant compliance challenges for companies like Neil Miao's, who struggle with understanding and providing the required information.
Chinese biotech companies are pursuing global commercialization despite US regulatory barriers, leveraging cost advantages in markets like Europe. Insilico Medicine's Ren Feng highlighted the need for internationalization and the challenge of lacking overseas clinical teams, suggesting business development deals as a solution.
A consortium led by Lakshmi N Mittal, Aditya Mittal and Adar Poonawala has acquired the IPL franchise Rajasthan Royals along with sister entities Paarl Royals and Barbados Royals for approximately $1.65 billion. The Mittal family will own 75%, Poonawala 18% and existing investors approximately 7%, with the deal expected to close in Q3 2026 after regulatory approvals from BCCI and CCI.
A consortium led by Lakshmi N. Mittal, Aditya Mittal, and Adar Poonawalla has acquired the IPL franchise Rajasthan Royals along with sister entities Paarl Royals and Barbados Royals for approximately $1.65 billion. The Mittal family will own 75%, Poonawala 18%, and existing investors approximately 7%. The deal requires regulatory approvals from BCCI, CCI, and IPL Governing Council, expected to conclude in Q3 2026.
